vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
OLAPLEX HOLDINGS, INC. is the larger business by last-quarter revenue ($105.1M vs $83.5M, roughly 1.3× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -12.5%, a 19.3% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 4.3%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
BLLN vs OLPX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $105.1M |
| Net Profit | $5.7M | $-13.1M |
| Gross Margin | 69.9% | 68.0% |
| Operating Margin | 11.5% | -4.3% |
| Net Margin | 6.8% | -12.5% |
| Revenue YoY | 117.4% | 4.3% |
| Net Profit YoY | 138.3% | -48.9% |
| EPS (diluted) | $0.10 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $105.1M | ||
| Q3 25 | $83.5M | $114.6M | ||
| Q2 25 | — | $106.3M | ||
| Q1 25 | — | $97.0M | ||
| Q4 24 | — | $100.7M | ||
| Q3 24 | $38.4M | $119.1M | ||
| Q2 24 | — | $103.9M | ||
| Q1 24 | — | $98.9M |
| Q4 25 | — | $-13.1M | ||
| Q3 25 | $5.7M | $11.1M | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | — | $465.0K | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-14.9M | $14.8M | ||
| Q2 24 | — | $5.8M | ||
| Q1 24 | — | $7.7M |
| Q4 25 | — | 68.0% | ||
| Q3 25 | 69.9% | 69.1% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.3% | ||
| Q3 24 | 52.6% | 68.6% | ||
| Q2 24 | — | 69.7% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | — | -4.3% | ||
| Q3 25 | 11.5% | 3.7% | ||
| Q2 25 | — | -1.1% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -32.9% | 23.5% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 19.8% |
| Q4 25 | — | -12.5% | ||
| Q3 25 | 6.8% | 9.7% | ||
| Q2 25 | — | -7.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | -8.7% | ||
| Q3 24 | -38.8% | 12.4% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 7.8% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | $0.10 | $0.02 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | $-1.47 | $0.02 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $318.7M |
| Total DebtLower is stronger | $55.0M | $352.3M |
| Stockholders' EquityBook value | $-239.5M | $879.4M |
| Total Assets | $327.5M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $318.7M | ||
| Q3 25 | $195.2M | $286.4M | ||
| Q2 25 | — | $289.3M | ||
| Q1 25 | — | $580.9M | ||
| Q4 24 | — | $586.0M | ||
| Q3 24 | — | $538.8M | ||
| Q2 24 | — | $507.9M | ||
| Q1 24 | — | $507.5M |
| Q4 25 | — | $352.3M | ||
| Q3 25 | $55.0M | $352.1M | ||
| Q2 25 | — | $351.9M | ||
| Q1 25 | — | $649.1M | ||
| Q4 24 | — | $650.5M | ||
| Q3 24 | — | $651.8M | ||
| Q2 24 | — | $653.1M | ||
| Q1 24 | — | $654.4M |
| Q4 25 | — | $879.4M | ||
| Q3 25 | $-239.5M | $888.7M | ||
| Q2 25 | — | $874.2M | ||
| Q1 25 | — | $878.3M | ||
| Q4 24 | — | $874.4M | ||
| Q3 24 | $-242.9M | $879.7M | ||
| Q2 24 | — | $863.3M | ||
| Q1 24 | — | $855.7M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $327.5M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.40× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $32.7M |
| Free Cash FlowOCF − Capex | $6.5M | $32.6M |
| FCF MarginFCF / Revenue | 7.7% | 31.0% |
| Capex IntensityCapex / Revenue | 8.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $32.7M | ||
| Q3 25 | $13.8M | $8.0M | ||
| Q2 25 | — | $20.9M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $49.7M | ||
| Q3 24 | — | $33.5M | ||
| Q2 24 | — | $16.2M | ||
| Q1 24 | — | $43.7M |
| Q4 25 | — | $32.6M | ||
| Q3 25 | $6.5M | $7.9M | ||
| Q2 25 | — | $20.8M | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | — | $49.2M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $16.1M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | — | 31.0% | ||
| Q3 25 | 7.7% | 6.9% | ||
| Q2 25 | — | 19.6% | ||
| Q1 25 | — | -3.1% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 28.0% | ||
| Q2 24 | — | 15.5% | ||
| Q1 24 | — | 43.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 8.8% | 0.1% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | 2.81× | ||
| Q1 24 | — | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
